Letrozole in Patients With Hepatopulmonary Syndrome

Status Terminated

Clinical Trial Summary

The purpose of this study is to assess the safety, tolerability and possible benefit of letrozole compared to placebo in patients with Hepatopulmonary Syndrome.

Clinical Trial Description

This study is a phase II randomized, double-blind, placebo-controlled parallel trial of 20 subjects with hepatopulmonary syndrome designed to assess the effect of letrozole 2.5 mg orally daily or placebo for 6 months on the alveolar-arterial oxygen gradient (AaPO2). Subjects at each site will be screened at outpatient clinic visit appointments and interested qualified subjects will be consented and offered participation in this trial. Once consent has been obtained baseline values will be established and subjects will begin letrozole with follow-up clinic visits and testing at 3 months, and 6 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04577001
Study type	Interventional
Source	Mayo Clinic
Contact
Status	Terminated
Phase	Phase 2
Start date	February 18, 2021
Completion date	March 26, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01676597` - Efficacy of Pentoxifylline and Rifaximin Combination in Pentoxifylline Refractory Clinical and Subclinical Hepatopulmonary Syndrome	N/A
Terminated	`NCT01518595` - Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis	Phase 2
Completed	`NCT00362752` - A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome	Phase 2
Active, not recruiting	`NCT03092401` - Hepatopulmonary Syndrome and Postoperative Complications After Liver Transplantation : A Case-control Study	N/A
Not yet recruiting	`NCT05373134` - Efficacy and Safety of Pentoxifylline in Improving Oxygenation in Hepatopulmonary Syndrome	N/A
Terminated	`NCT02021929` - Sorafenib for Hepatopulmonary Syndrome	Phase 2
Completed	`NCT02148536` - Effect of Transjugular Intrahepatic Portosystemic Shunt on Oxygenation in Cirrhotic Patients With Hepatopulmonary Syndrome
Terminated	`NCT00593658` - Pilot Study of Pentoxifylline for Hepatopulmonary Syndrome	Phase 1
Recruiting	`NCT03435406` - Investigation of the Prevalence of Hepatopulmonary Syndrome in Cirrhosis Patients Caused by Hepatitis B in Western China	N/A
Recruiting	`NCT04004104` - Supine Exercise in Hepatopulmonary Syndrome Patients With Orthodeoxia	N/A